-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53

Benzinga·10/08/2026 10:41:51
語音播報
Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and lowers the price target from $59 to $53.